Aumolertinib, a novel third-generation EGFR-TKI, has been used to treat NSCLC EGFR T790M-positive patients with progressive disease or recurrence as an alternative to other EGFR TKI therapies (32). This evidence concerns the gene EGFR and non-small cell lung carcinoma.